SCHEMBL6685908

SCHEMBL6685908

C=C(CCCNC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.57
GAA P10253 1/20 0.57
KMT2A Q03164 1/20 0.57
TDP1 Q9NUW8 1/20 0.56
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
CA1 P00915 10/20 0.47
CA2 P00918 10/20 0.47
CA12 O43570 6/20 0.47
CA9 Q16790 6/20 0.47
SIGMAR1 Q99720 1/20 0.42
CHRM2 P08172 2/20 0.40
CHRM4 P08173 2/20 0.40
CHRM5 P08912 2/20 0.40
CHRM1 P11229 2/20 0.40
CHRM3 P20309 2/20 0.40
EPHX1 P07099 1/20 0.40
HTT P42858 1/20 0.40
STK17B O94768 1/20 0.39
STK17A Q9UEE5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1882369 0.94 TDP1 (0.61) MEN1GAAKMT2ATDP1MAOA
SCHEMBL26859671 0.90 MEN1 (0.54) MEN1GAAKMT2ATDP1MAOA
SCHEMBL4926959 0.90 GAA (0.51) MEN1GAAKMT2ATDP1MAOA
SCHEMBL13419528 0.86 MEN1 (0.60) MEN1GAAKMT2ATDP1MAOA
SCHEMBL7272725 0.83 MEN1 (0.60) MEN1GAAKMT2ATDP1MAOA
SCHEMBL26859657 0.83 TDP1 (0.51) MEN1GAAKMT2ATDP1MAOA
SCHEMBL7426739 0.82 TDP1 (0.62) MEN1GAAKMT2ATDP1MAOA
SCHEMBL238415 0.82 MEN1 (0.64) MEN1GAAKMT2ATDP1MAOA
SCHEMBL13504177 0.82 EPHX1 (0.50) MEN1GAAKMT2ATDP1EPHX1
SCHEMBL22975179 0.81 TDP1 (0.50) MEN1GAAKMT2ATDP1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030244-B1 POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO ARROWHEAD PHARMACEUTICALS INC (US) 2021-04-21 EP disclosed
US-20170022497-A1 Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo Arrowhead Pharmaceuticals, Inc. 2017-01-26 US disclosed
US-9487556-B2 Polyconjugates for delivery of RNAi triggers to tumor cells in vivo Arrowhead Pharmaceuticals, Inc. (US) 2016-11-08 US disclosed
US-9452221-B2 Poly(acrylate) polymers for in vivo nucleic acid delivery Arrowhead Pharmaceuticals, Inc. (US) 2016-09-27 US disclosed
US-20150104408-A1 Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery Arrowhead Madison Inc. (US) 2015-04-16 US disclosed
EP-2838544-A1 POLY(ACRYLATE) POLYMERS FOR IN VIVO NUCLEIC ACID DELIVERY Arrowhead Research Corporation (US) 2015-02-25 EP disclosed
US-20150045573-A1 Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo Arrowhead Pharmaceuticals, Inc. 2015-02-12 US disclosed
US-8933047-B2 Poly(acrylate) polymers for in vivo nucleic acid delivery Arrowhead Madison Inc. (US) 2015-01-13 US disclosed
US-8802773-B2 In vivo polynucleotide delivery conjugates having enzyme sensitive linkages Arrowhead Madison Inc. (US) 2014-08-12 US disclosed
US-20130317079-A1 Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery Arrowhead Madison Inc. (US) 2013-11-28 US disclosed
WO-2013158141-A1 POLY(ACRYLATE) POLYMERS FOR IN VIVO NUCLEIC ACID DELIVERY ARROWHEAD RESEARCH CORPORATION (US) 2013-10-24 WO disclosed
US-20130190484-A1 In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages Arrowhead Madison Inc. (US) 2013-07-25 US disclosed
US-8426554-B2 In vivo polynucleotide delivery conjugates having enzyme sensitive linkages Arrowhead Madison Inc. (US) 2013-04-23 US disclosed
US-20120172412-A1 In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages Arrowhead Madison Inc. (US) 2012-07-05 US disclosed
WO-2004074335-A1 NOVEL CATIONIC POLYMERS AND COPOLYMERS, USE THEREOF FOR THE VECTORISATION OF BIOMOLECULES AND SYNTHETIC INTERMEDIATES FOR THE SAME HALISOL (FR) 2004-09-02 WO disclosed
EP-0821018-A2 Crosslinkable olefinic polymers and method for their preparation PCD-Polymere Gesellschaft m.b.H. (AT) 1998-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130317079-A1 Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery PHAX, PARN, PARG MEN1 3008/4885GAA 1031/4885KMT2A 3056/4885
US-20170022497-A1 Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo PAM, PLAUR, M6PR MEN1 483/4885GAA 453/4885KMT2A 734/4885
US-20150045573-A1 Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo PAM, PLAUR, M6PR MEN1 483/4885GAA 453/4885KMT2A 734/4885
US-20120172412-A1 In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages RNASE1, PNKP, POLM MEN1 1759/4885GAA 91/4885KMT2A 949/4885
US-20130190484-A1 In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages RNASE1, PNKP, POLM MEN1 1759/4885GAA 91/4885KMT2A 949/4885
US-20150104408-A1 Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery PHAX, PARN, PARG MEN1 3008/4885GAA 1031/4885KMT2A 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.